415 related articles for article (PubMed ID: 29190241)
1. AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: The ARI2 Study.
Blanco-Garavito R; Jung C; Uzzan J; Quaranta-ElMaftouhi M; Coscas F; Sahel J; Korobelnik JF; Béchet S; Querques G; Souied EH
Retina; 2018 Dec; 38(12):2285-2292. PubMed ID: 29190241
[TBL] [Abstract][Full Text] [Related]
2. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept.
Tyagi P; Juma Z; Hor YK; Scott NW; Ionean A; Santiago C
BMC Ophthalmol; 2018 Jun; 18(1):148. PubMed ID: 29929478
[TBL] [Abstract][Full Text] [Related]
3. QUANTITATIVE ANALYSIS OF PIGMENT EPITHELIAL DETACHMENT RESPONSE TO DIFFERENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN WET AGE-RELATED MACULAR DEGENERATION.
Balaskas K; Karampelas M; Horani M; Hotu O; Keane P; Aslam T
Retina; 2017 Jul; 37(7):1297-1304. PubMed ID: 27755376
[TBL] [Abstract][Full Text] [Related]
4. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kim K; Kim ES; Kim Y; Yang JH; Yu SY; Kwak HW
Retina; 2019 Feb; 39(2):303-313. PubMed ID: 29160779
[TBL] [Abstract][Full Text] [Related]
5. WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lam D; Semoun O; Blanco-Garavito R; Jung C; Nguyen DT; Souied EH; Mimoun G
Retina; 2018 Jun; 38(6):1100-1109. PubMed ID: 28520639
[TBL] [Abstract][Full Text] [Related]
6. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
[TBL] [Abstract][Full Text] [Related]
7. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
[TBL] [Abstract][Full Text] [Related]
8. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
[TBL] [Abstract][Full Text] [Related]
9. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
[TBL] [Abstract][Full Text] [Related]
10. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
[TBL] [Abstract][Full Text] [Related]
11. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
13. One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study.
Veritti D; Sarao V; Parravano M; Arias L; Varano M; Lanzetta P
Eur J Ophthalmol; 2017 Jan; 27(1):74-79. PubMed ID: 27791249
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration.
Rouvas A; Chatziralli I; Androu A; Mpougatsou P; Alonistiotis D; Douvali M; Kabanarou SA; Theodossiadis P
Int Ophthalmol; 2019 Feb; 39(2):431-440. PubMed ID: 29404860
[TBL] [Abstract][Full Text] [Related]
15. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
Park DH; Sun HJ; Lee SJ
Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
[TBL] [Abstract][Full Text] [Related]
16. GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
de Massougnes S; Dirani A; Mantel I
Retina; 2018 Apr; 38(4):717-724. PubMed ID: 28368974
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration.
Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA
Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921
[TBL] [Abstract][Full Text] [Related]
18. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.
Muftuoglu IK; Tsai FF; Gaber R; Alam M; Meshi A; Freeman WR
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):709-717. PubMed ID: 27878592
[TBL] [Abstract][Full Text] [Related]
19. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
[TBL] [Abstract][Full Text] [Related]
20. INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB: A Treat-and-Extend Trial.
Hatz K; Prünte C
Retina; 2017 Jun; 37(6):1185-1192. PubMed ID: 27652915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
